JAVIER
PUENTE VÁZQUEZ
Profesor asociado de Ciencias de la Salud
Hospital Universitario La Paz
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario La Paz (16)
2024
-
Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1)
British Journal of Cancer, Vol. 130, Núm. 3, pp. 434-441
2022
-
Genomic Landscape of Vinflunine Response in Metastatic Urothelial Cancer
Cancers, Vol. 14, Núm. 2
-
Measures to evaluate quality of care in renal cancer: results of a Delphi study in Spain
Clinical and Translational Oncology, Vol. 24, Núm. 3, pp. 495-502
2021
2019
-
Correction to: SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016) (Clinical and Translational Oncology, (2016), 18, 12, (1197-1205), 10.1007/s12094-016-1584-z)
Clinical and Translational Oncology
-
Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: Results from a prospective observational study (CAPRO)
BMC Cancer, Vol. 19, Núm. 1
-
Prorepair-B: A prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer
Journal of Clinical Oncology, Vol. 37, Núm. 6, pp. 490-503
-
Real-world outcome of 173 metastatic non-clear cell renal cell carcinoma (nccrcc) cases: The experience of the center group for genitourinary tumors
Kidney Cancer, Vol. 3, Núm. 1, pp. 41-50
-
The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG)
Targeted Oncology, Vol. 14, Núm. 1, pp. 15-32
2017
-
Recent advances in genitourinary tumors: A review focused on biology and systemic treatment
Critical Reviews in Oncology/Hematology, Vol. 113, pp. 171-190
2016
-
Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations
Targeted Oncology, Vol. 11, Núm. 2, pp. 129-141
-
Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study
BMC Cancer, Vol. 16, Núm. 1
-
Retrospective analysis of metastatic non-clear cell renal carcinoma (NCCRC): the Spanish Grupo Centro Experience
Annals of Oncology, Vol. 27, pp. vi290
-
SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016)
Clinical and Translational Oncology, Vol. 18, Núm. 12, pp. 1197-1205
2015
-
Recomendaciones para el diagnóstico radiológico y la valoración de la respuesta terapéutica en el cáncer de pulmón. Consenso nacional de la Sociedad Española de Radiología Médica y la Sociedad Española de Oncología Médica
Radiologia, Vol. 57, Núm. 1, pp. 66-78
-
Recommendations for radiological diagnosis and assessment of treatment response in lung cancer: a national consensus statement by the Spanish Society of Medical Radiology and the Spanish Society of Medical Oncology
Clinical and Translational Oncology, Vol. 17, Núm. 1, pp. 11-23